- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- Ensuring access to chronic pain medications
- FDA approves first single-entity, extended-release hydrocodone drug
- Actavis seeks approval for generic opioid-dependence drug
MALVERN, Pa. — Shionogi and Egalet have entered a deal worth up to $425 million for the development of abuse-deterrent opioid painkillers, Egalet said.
The deal centers on the development and potential commercialization of experimental drugs containing the opioid painkiller hydrocodone.
Shionogi will pay Egalet $10 million upfront and purchase $15 million worth of its stock, as well as $300 million or more in milestone payments based on development and approval of products under the agreement. Egalet also is eligible to receive royalties and sales-based milestones of $100 million or more.